Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker.
作者： Hideki Mori , Hidekazu Suzuki
DOI: 10.5056/JNM18139
关键词:
摘要: Proton pump inhibitors are commonly utilized for the treatment of gastric acid-related diseases, such as gastroesophageal reflux disease, peptic ulcer and Helicobacter pylori infection, prevention low-dose aspirin or nonsteroidal anti-inflammatory drug-induced ulcers. Vonoprazan is a first-in-class potassium-competitive acid blocker, which has distinct advantages compared to other conventional proton in terms efficacy suppression. Due its strong suppression capabilities, vonoprazan serves an effective drug disease H. infection.
elsevier.com
kstudy.com
sci-hub.se 参考文章(78)
Yu-Han Chang, Yang-Pei Chang, Shu-Yu Tai, Chen-Yu Chien, Deng-Chyang Wu, Kun-Der Lin, Bo-Lin Ho, Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan PLOS ONE. ,vol. 12, ,(2017) , 10.1371/JOURNAL.PONE.0171006
Toshihiro Nishizawa, Hidekazu Suzuki, Ai Fujimoto, Hiroto Kinoshita, Shuntaro Yoshida, Yoshihiro Isomura, Akira Toyoshima, Takanori Kanai, Naohisa Yahagi, Osamu Toyoshima, Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection. Journal of Clinical Biochemistry and Nutrition. ,vol. 60, pp. 208- 210 ,(2017) , 10.3164/JCBN.16-86
Katsuhiko Iwakiri, Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto, Kentaro Kudou, Akira Nishimura, Naoki Hiramatsu, Eiji Umegaki, Kiyoshi Ashida, A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therapeutic Advances in Gastroenterology. ,vol. 10, pp. 439- 451 ,(2017) , 10.1177/1756283X17705329
S. Yi, H. Lee, S. B. Jang, H. M. Byun, S. H. Yoon, J.-Y. Cho, I.-J. Jang, K.-S. Yu, A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers. Alimentary Pharmacology & Therapeutics. ,vol. 46, pp. 337- 346 ,(2017) , 10.1111/APT.14148
Derk C.F. Klatte, Alessandro Gasparini, Hong Xu, Pietro de Deco, Marco Trevisan, Anna L.V. Johansson, Björn Wettermark, Johan Ärnlöv, Cynthia J Janmaat, Bengt Lindholm, Friedo W. Dekker, Josef Coresh, Morgan E. Grams, Juan J. Carrero, Association between proton pump inhibitor use and risk of progression of chronic kidney disease Gastroenterology. ,vol. 153, pp. 702- 710 ,(2017) , 10.1053/J.GASTRO.2017.05.046
Cheng-yuan Li, Mei Su, Yun-yi Yan, Lin Zhou, Lu-yao Ao, Wei-rong Fang, Yun-man Li, KFP-H008 blocks gastric acid secretion through inhibiting H+-K+-ATPase European Journal of Pharmacology. ,vol. 810, pp. 112- 119 ,(2017) , 10.1016/J.EJPHAR.2017.06.020
Satoshi Shinozaki, Hiroyuki Osawa, Yoshikazu Hayashi, Hirotsugu Sakamoto, Yasutoshi Kobayashi, Alan Kawarai Lefor, Hironori Yamamoto, Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor‑resistant gastroesophageal reflux disease Biomedical Reports. ,vol. 7, pp. 231- 235 ,(2017) , 10.3892/BR.2017.947
Khagendra Dahal, Sharan P. Sharma, Jaspreet Kaur, Billie J. Anderson, Gurpinder Singh, Efficacy and Safety of Proton Pump Inhibitors in the Long-Term Aspirin Users: A Meta-Analysis of Randomized Controlled Trials. American Journal of Therapeutics. ,vol. 24, ,(2017) , 10.1097/MJT.0000000000000637
C. Prakash Gyawali, Ronnie Fass, Management of Gastroesophageal Reflux Disease Gastroenterology. ,vol. 154, pp. 302- 318 ,(2017) , 10.1053/J.GASTRO.2017.07.049
Yuji Mizokami, Kazunori Oda, Nobuo Funao, Akira Nishimura, Satoshi Soen, Takashi Kawai, Kiyoshi Ashida, Kentaro Sugano, Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. ,vol. 67, pp. 1042- 1051 ,(2018) , 10.1136/GUTJNL-2017-314010